Cargando…
LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review
BACKGROUND: Artifactual Hypoglycemia (AH), is defined as a discrepancy between the measured and actual blood glucose level. The absence of classical symptoms of hypoglycemia in patients with low measured glucose levels should raise the suspicion of AH. Here we describe a case of AH in a patient with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624759/ http://dx.doi.org/10.1210/jendso/bvac150.541 |
_version_ | 1784822313395421184 |
---|---|
author | Mohammed ALShehri, Sara Enani, Jawaher Alfadda, Assim Abdulaziz AlSofiani, Mohammed |
author_facet | Mohammed ALShehri, Sara Enani, Jawaher Alfadda, Assim Abdulaziz AlSofiani, Mohammed |
author_sort | Mohammed ALShehri, Sara |
collection | PubMed |
description | BACKGROUND: Artifactual Hypoglycemia (AH), is defined as a discrepancy between the measured and actual blood glucose level. The absence of classical symptoms of hypoglycemia in patients with low measured glucose levels should raise the suspicion of AH. Here we describe a case of AH in a patient with chronic myeloid leukemia (CML). CLINICAL CASE: A 47-year-old woman was hospitalized for the evaluation of a four-month history of headache, anorexia, and weight loss. After further workup, she was diagnosed with CML; and upon evaluation, she was found to have a very low serum glucose level of 22 mg/dL. She reported no symptoms of hypoglycemia at the time and no personal or family history of diabetes. She was not using any glucose-lowering medication. Physical examination findings, including vital signs, were unremarkable. Laboratory studies revealed a serum glucose of 22 mg/dL with a simultaneous point-of-care (POC) capillary glucose level of 81 mg/dL. This discrepancy in glucose levels raised the suspicion of artifactual hypoglycemia. To further explore this, we drew three simultaneous venous blood samples and processed them differently to examine the impact of sample processing on serum glucose level in this patient. Two samples were drawn in tubes with no antiglycolytic agent (one sample was centrifuged immediately after the blood draw, and the second one was processed 5 hours after the blood draw). Whereas, the third sample was drawn in a tube containing sodium fluoride, an inhibitor of aerobic glycolysis, and was processed after one hour of the blood draw. Glucose concentrations in the three samples were as follows: 79 mg/dl, 41.4 mg/dl, and 77.4 mg/dl, respectively. The diagnosis of artifactual hypoglycemia due to excessive glucose consumption by leukocytes was established based on the findings of normal capillary blood glucose and normal plasma glucose levels when a tube prefilled with a glycolysis inhibitor is used. CONCLUSION: Artifactual hypoglycemia should be considered in patients with asymptomatic hypoglycemia, especially when there is a discrepancy between the capillary and venous glucose levels. Patients with marked leukocytosis can have artifactually low serum glucose, an erroneous finding that can be mitigated by a) rapid processing of the blood sample or b) utilization of tubes pre-filled with a glycolysis inhibitor. Presentation: No date and time listed |
format | Online Article Text |
id | pubmed-9624759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-96247592022-11-14 LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review Mohammed ALShehri, Sara Enani, Jawaher Alfadda, Assim Abdulaziz AlSofiani, Mohammed J Endocr Soc Diabetes & Glucose Metabolism BACKGROUND: Artifactual Hypoglycemia (AH), is defined as a discrepancy between the measured and actual blood glucose level. The absence of classical symptoms of hypoglycemia in patients with low measured glucose levels should raise the suspicion of AH. Here we describe a case of AH in a patient with chronic myeloid leukemia (CML). CLINICAL CASE: A 47-year-old woman was hospitalized for the evaluation of a four-month history of headache, anorexia, and weight loss. After further workup, she was diagnosed with CML; and upon evaluation, she was found to have a very low serum glucose level of 22 mg/dL. She reported no symptoms of hypoglycemia at the time and no personal or family history of diabetes. She was not using any glucose-lowering medication. Physical examination findings, including vital signs, were unremarkable. Laboratory studies revealed a serum glucose of 22 mg/dL with a simultaneous point-of-care (POC) capillary glucose level of 81 mg/dL. This discrepancy in glucose levels raised the suspicion of artifactual hypoglycemia. To further explore this, we drew three simultaneous venous blood samples and processed them differently to examine the impact of sample processing on serum glucose level in this patient. Two samples were drawn in tubes with no antiglycolytic agent (one sample was centrifuged immediately after the blood draw, and the second one was processed 5 hours after the blood draw). Whereas, the third sample was drawn in a tube containing sodium fluoride, an inhibitor of aerobic glycolysis, and was processed after one hour of the blood draw. Glucose concentrations in the three samples were as follows: 79 mg/dl, 41.4 mg/dl, and 77.4 mg/dl, respectively. The diagnosis of artifactual hypoglycemia due to excessive glucose consumption by leukocytes was established based on the findings of normal capillary blood glucose and normal plasma glucose levels when a tube prefilled with a glycolysis inhibitor is used. CONCLUSION: Artifactual hypoglycemia should be considered in patients with asymptomatic hypoglycemia, especially when there is a discrepancy between the capillary and venous glucose levels. Patients with marked leukocytosis can have artifactually low serum glucose, an erroneous finding that can be mitigated by a) rapid processing of the blood sample or b) utilization of tubes pre-filled with a glycolysis inhibitor. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9624759/ http://dx.doi.org/10.1210/jendso/bvac150.541 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Diabetes & Glucose Metabolism Mohammed ALShehri, Sara Enani, Jawaher Alfadda, Assim Abdulaziz AlSofiani, Mohammed LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review |
title | LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review |
title_full | LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review |
title_fullStr | LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review |
title_full_unstemmed | LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review |
title_short | LBODP031 Evaluation Of Artifactual Hypoglycemia: A Case-based Review |
title_sort | lbodp031 evaluation of artifactual hypoglycemia: a case-based review |
topic | Diabetes & Glucose Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624759/ http://dx.doi.org/10.1210/jendso/bvac150.541 |
work_keys_str_mv | AT mohammedalshehrisara lbodp031evaluationofartifactualhypoglycemiaacasebasedreview AT enanijawaher lbodp031evaluationofartifactualhypoglycemiaacasebasedreview AT alfaddaassimabdulaziz lbodp031evaluationofartifactualhypoglycemiaacasebasedreview AT alsofianimohammed lbodp031evaluationofartifactualhypoglycemiaacasebasedreview |